Reach Us +1-947-333-4405


Bopda-Waffo A | OMICS International
ISSN: 2332-0877

Journal of Infectious Diseases & Therapy
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences
Indexed In
  • Index Copernicus
  • Google Scholar
  • Open J Gate
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • Publons
  • Euro Pub
Share This Page

Bopda-Waffo A

Associate Professor of Biology Dept. of Biological Sciences University of Alabama USA


Dr. Bopda Waffo received both BS and MS degrees from the University of Yaoundé in Cameroon. Dr. Bopda obtained his PhD from Max-Planck-Institute for Biophysical Chemistry of Gottingen in Germany. Dr. Bopda was a post-doctoral researcher in the Universities of Medicine and Dentistry of New Jersey and in the University of Texas in Houston and Galveston. Dr. Waffo was also a research associate in the Department of Microbiology at the University of Alabama at Birmingham, Birmingham Alabama.

Research Interest

Dr. Waffo’s research focuses are as follows: a) RNA-coliphage display as drug cargo and b) immunization with recombinant antigenic polypeptides or proteins coupled to nano-particles. Phage display is a molecular diversity technology that allows gene modification of phage and presentation of biomolecules on its surface. Qphage was shown to be a powerful tool for functional molecules exposition and optimization (Bopda, 2004). More recently Dr. Waffo investigated cellular proteins interacting with the viral proteins during viral infection. Dr. Waffo developed expertise in protein purification and RNA phage display technology. He will be using his expertise and nanotechnology to explore viral shell as well as recombinant antigenic polypeptide for the attachment of drug cargo.